Caladrius Biosciences Inc. (NASDAQ:CLBS) Stock Sees Selling Pressure At Higher Level

September 2, 2021

Caladrius Biosciences Inc. (NASDAQ: CLBS) fell 2.3% after announcing Dr. Kristen K. Buck’s appointment as the company’s Chief Medical Officer (CMO). Buck is joining the company from ICON plc, where she served in the position of CMO. She represented ICON’s position on major scientific, medical governance, and ethical matters and offered oversight and guidance to scientific and medical groups. Before that, she worked at Optum Insights as an SVP and…

Read More >>

Caladrius Biosciences Inc. (NASDAQ: CLBS) Jumps 4.5% After FDA Approves Its CLBS201 IND in Diabetic Kidney Disease

June 29, 2021

Caladrius Biosciences Inc. (NASDAQ: CLBS) climbed 4.46% after the FDA approved its Investigational New Drug Application for the CLBS201 study. CLBS201 is a CD34+ cell therapy for diabetic kidney disease treatment.  Caladrius evaluating CLBS20’s efficacy and safety  David J. Mazzo, the company’s CEO and President said, “Our latest development program, CLBS201, is designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic patients with…

Read More >>